NeuroSearch Plans To Develop Anxiolytic Following P&U Termination
Executive Summary
NeuroSearch anticipates continuing development of the GABA modulator NS2710, following a March 5 announcement that Pharmacia & Upjohn will terminate its licensing agreement for the anxiety disorder therapy.